04 Apr 2023
A joint safety alert has been issued from the British Menopause Society, Faculty of Sexual & Reproductive Healthcare, Royal College of General Practitioners, Royal College of Obstetricians & Gynaecologists, Society for Endocrinology and the Royal College of Nursing Women’s Health Forum.
This safety alert has been produced in response to questions raised in relation to appropriate doses of oestrogen and progestogen provided to women experiencing symptoms of menopause.
Current National Institute for Health and Care Excellence (NICE), MHRA and national and international guidance recommends the lowest effective dose to control symptoms, but an increasing numbers of women are being initiated on high doses of oestrogen which exceed the product licenses, not in line with any clinical guidelines.
Read the alert in full.
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024
Surgery for hypoparathyroidism sees reduced facture rates
19 Apr 2024
Patients with type 2 diabetes taking antidepressants have a higher mortality risk
19 Apr 2024
Endocrine-disrupting chemical levels found at alarming levels in Australia
11 Apr 2024